Satellos Bioscience Inc.
TSX:MSCL.TOBiotechnology
+$0.01 today
- Market cap
- $182.89M
- Beta
- 1.17
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.32
Volume 0.01M
Average 0.02M
MSCL.TO Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Satellos Bioscience Inc.TSX: MSCL.TO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows 40.1% year over year
Q1 FY2026 depreciation & amortization of $983.61 rose 40.1% year over year. Sequentially, it fell 3.1% from the prior quarter. Over 3 fiscal years it compounded at -75.3% a year.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
Mixed currencies · from the income statement
- Latest · FY2025
- 5.09K USD
- Year-over-year change
- —
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.09K | — |
| FY2024 | 2024-12-31 | 20K | +185.7% |
| FY2023 | 2023-12-31 | 7K | -97.9% |
| FY2022 | 2022-12-31 | 337K | +103.4% |
| FY2021 | 2021-12-31 | 165.69K | — |
Depreciation & Amortization vs competitors
How MSCL.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Over three fiscal years its annual growth of -75.3% compares with a peer median of -8.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | CA$256.13K CAD | -40.2% | -8.0% | — | |
| LTM Mar 2026 | CA$103.71K CAD | -69.2% | -22.6% | — | |
MSCL.TOSatellos Bioscience Inc. | LTM Mar 2026 | $5.73K USD | — | -75.3% | — |
| LTM Apr 2026 | CA$5K CAD | -58.3% | -5.9% | — | |
| Peer median (excluding MSCL.TO) | — | -58.3% | -8.0% | — | |
Competitors are the stored peer set for MSCL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · CAD | FY2024 Dec 2024 · CAD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 165.69K | 3.73M | 8.82M | 20K | 5.09K |
| Gross Profit | (165.69K) | (3.73M) | (8.82M) | (20K) | (5.09K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 1.88M | 2.59M | 8.82M | 19.6M | 18.75M |
| Selling, General & Admin | 2.8M | 5.49M | 6.64M | 8.19M | 7.44M |
| Operating Expenses | 4.7M | 4.69M | 15.46M | 27.79M | 26.92M |
| Depreciation & Amortization | 165.69K | 337K | 7K | 20K | 5.09K |
| EBITDA | (4.6M) | (8.09M) | (15.71M) | (28.08M) | (26.92M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (6.65M) | (8.43M) | (15.46M) | (27.81M) | (26.92M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 7.99K | 63K | 1.33M | 1.37M | 1.38M |
| Interest Expense | 985.33K | 0 | 177K | 0 | 0 |
| Other Income / Expenses | (8.86M) | (2.89M) | (426K) | (291K) | 1.79M |
| Income Before Tax | (15.51M) | (11.32M) | (15.89M) | (28.1M) | (25.13M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (42.41K) | 5K | 0 | 0 | 175.01K |
| Net Income | (15.51M) | (11.32M) | (15.89M) | (28.1M) | (25.31M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (7.73) | (3.81) | (2.21) | (2.94) | (1.73) |
| EPS (Diluted) | (7.73) | (3.81) | (2.21) | (2.94) | (1.73) |
| Weighted Avg Shares | 2.01M | 2.97M | 7.2M | 9.56M | 14.6M |
| Weighted Avg Shares (Diluted) | 2.01M | 2.97M | 7.2M | 9.56M | 14.6M |
Satellos Bioscience Inc.
TSX:MSCL.TO
Intrinsic Alpha fair value
Locked
Current Price
$8.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.